- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05128721
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a Phase I, Randomized, Open-Labeled Clinical trial. Eligible volunteers will be randomized in a 1:1:1 allocation ratio, into one of the three study arms using the Interactive Web Response Technology (IWRS).
Unscheduled visits can occur at any time during the study period outside the initially planned study visits, all the extra visits will be documented in the subjects' files. Volunteers will be randomized into one of the following arms to receive different doses of the Inactivated
SARS-COV-2 Vaccine "NRC-VACC-101" as an intramuscular (IM) Injection or Placebo:
Arm One:
Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
Arm Two:
Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
Arm Three (Control arm):
Volunteers will receive two IM doses of the placebo, 28 days apart. The first 9 subjects will be initially vaccinated with their first dose, as per their assigned study arm determined by the randomization procedures and will be followed up until day 14 (visit 03). At this point in the study, the Data Safety and Monitoring Board (DSMB) will review safety data before proceeding with vaccinating the rest of the recruited subjects
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Osama Azmy, MD
- Número de teléfono: +201223103084
- Correo electrónico: osamaazmy@yahoo.com
Copia de seguridad de contactos de estudio
- Nombre: Clinical Trial Unit Clinical Trial Unit National Research Centre, MD
- Número de teléfono: +20237623009
- Correo electrónico: ctu.mrce@nrc.sci.eg
Ubicaciones de estudio
-
-
Giza
-
Cairo, Giza, Egipto, 12622
- Reclutamiento
- Medical Research Centre of Excellence National Research Centre
-
Contacto:
- Osama Azmy, MD
- Número de teléfono: +201223103084
- Correo electrónico: osamaazmy@yahoo.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults with age 18 to 50 years.
- Willingness.
- For married females of childbearing age: Willingness to practice continuous effective contraception for one year from the start of the study.
- Agreement to refrain from blood donation during the study.
- Body temperature is within the normal range (36.5 - 37.5°C).
- General good health as established by medical history, physical and laboratory examinations.
Exclusion Criteria:
- Pregnancy or lactation.
- Inability to provide informed consent.
- Recent receipt of any vaccination within 30 days prior to baseline.
- Planning to receive any vaccination during the course of the study.
- Prior receipt of Adenovirus vaccine, or any other Coronavirus vaccine.
- Recent receipt of any immunoglobulin within 90 days prior to baseline.
- Recent receipt of any blood product within 90 days prior to baseline.
Volunteers who are immunosuppressed or receiving immunosuppressive medications, including:
HIV infection, asplenia, recurrent severe infections, and the use of immunosuppressive medications within the past 6 months, except for topical steroids or short-term oral steroids (course lasting < 14 days).
- Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
- Having any autoimmune disease.
- History of allergic reactions for any of the vaccine components.
- History of angioedema.
- History of anaphylaxis.
- History of cancer.
- History of serious psychiatric conditions that are likely to affect participation in the study.
- Having bleeding disorders.
- Having chronic respiratory diseases.
- Having chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorders, and neurological illness.
- Volunteers with BMI ≥ 40 Kg/m2 or ≤ 18 Kg/m2.
- Current alcohol abuse.
- Drug abuse within 5 years prior to baseline.
- History of laboratory-confirmed COVID-19 or seropositivity for SARS-CoV-2 or positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS CoV-2 or abnormal chest CT-Scan (COVID-19 image) or positive pharyngeal/sputum swabs for SARS-CoV-2.
- Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
- High-risk population (volunteers who work in front-line health facilities or were in close contact with confirmed COVID-19 cases).
- Living in the same household as anyone at high risk of severe COVID-19.
- Any condition, according to the judgment of the investigator, that would interfere with the subject's ability to comply with all study requirements or that would place the subject at unacceptable risk by his/her participation in the study or impair the interpretation of the study data.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: NRC-VACC-101 vaccine 3 microgram
Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
Otros nombres:
|
Comparador activo: NRC-VACC-101 vaccine 6 microgram
Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
Otros nombres:
|
Comparador de placebos: Control arm
Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
The safety of NRC-VACC-101 Vaccine
Periodo de tiempo: Follow up for any solicited adverse event(AE) reported within 7 days
|
To evaluate the safety of the proposed regimens of NRC-VACC-101
|
Follow up for any solicited adverse event(AE) reported within 7 days
|
The tolerability of NRC-VACC-101 Vaccine
Periodo de tiempo: Follow up for any AE within 28 days of each dose
|
To evaluate the tolerability of the proposed regimens of NRC-VACC-101 Vaccine in the healthy population
|
Follow up for any AE within 28 days of each dose
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
The seroconversion rate of neutralizing antibodies
Periodo de tiempo: The evaluation of the antibody will be measured up to one month of each dose
|
To evaluate the seroconversion rate of neutralizing antibodies resulting from the NRC-VACC-101 Vaccine
|
The evaluation of the antibody will be measured up to one month of each dose
|
To recommend the dose level of NRC-VACC-101 Vaccine for the phase II trial.
Periodo de tiempo: The evaluation of the Microneutralization Assay will be assessed up to one month of each dose
|
The evaluation of the Microneutralization Assay curve will give an overview of the dose possible suggested dose of NRC-VACC-101 Vaccine for the phase II trial
|
The evaluation of the Microneutralization Assay will be assessed up to one month of each dose
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Osama Azmy, MD, Medical Research and Clinical Studies Institute National Research Centre, Dokki, Giza, Egypt.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por coronavirus
- Infecciones por coronaviridae
- Infecciones por Nidovirales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones del Tracto Respiratorio
- Enfermedades de las vías respiratorias
- Neumonía Viral
- Neumonía
- Enfermedades pulmonares
- COVID-19
- Efectos fisiológicos de las drogas
- Factores inmunológicos
- Vacunas
Otros números de identificación del estudio
- NO-B041
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre COVID-19
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera Niguarda... y otros colaboradoresTerminado
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustTerminado
-
Yang I. PachankisActivo, no reclutandoInfección respiratoria por COVID-19 | Síndrome de Estrés COVID-19 | Reacción adversa a la vacuna COVID-19 | Tromboembolismo asociado a COVID-19 | Síndrome Post-Cuidados Intensivos COVID-19 | Accidente cerebrovascular asociado con COVID-19Porcelana
-
Massachusetts General HospitalReclutamientoSíndrome posagudo de COVID-19 | COVID largo | Secuelas post agudas de COVID-19 | Largo COVID-19Estados Unidos
-
Population Health Research InstituteMcMaster University; Hamilton Health Sciences CorporationTerminadoCirugía | COVID-19 | Complicación perioperatoriaCanadá
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...TerminadoSecuelas post agudas de COVID-19 | Condición posterior a COVID-19 | Largo-COVID | Síndrome crónico de COVID-19Italia
-
Indonesia UniversityReclutamientoSíndrome Post-COVID-19 | COVID largo | Condición posterior a COVID-19 | Síndrome Post-COVID | Largo COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkAún no reclutandoSíndrome Post-COVID-19 | COVID largo | Largo Covid19 | Condición posterior a COVID-19 | Síndrome Post-COVID | Condición posterior a COVID-19, no especificada | Condición post-COVIDPaíses Bajos
-
Sheba Medical CenterDesconocido
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaReclutamientoPandemia de COVID-19 | Vacunas para COVID-19 | Enfermedad del virus COVID-19Indonesia
Ensayos clínicos sobre Covi Vax
-
Sorrento Therapeutics, Inc.Retirado
-
Sorrento Therapeutics, Inc.Retirado
-
Sorrento Therapeutics, Inc.Retirado
-
University of PennsylvaniaPhiladelphia Department of Public HealthTerminado
-
Chonnam National University HospitalDesconocidoMieloma múltipleCorea, república de
-
Entos Pharmaceuticals Inc.Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical Pharma... y otros colaboradoresTerminadoSARS-CoV-2Burkina Faso, Canadá, Senegal, Sudáfrica
-
Codagenix, IncTerminadoCOVID-19Reino Unido
-
Codagenix, IncTerminadoCOVID-19 | SARS-CoV-2Reino Unido
-
Sorrento Therapeutics, Inc.Reclutamiento
-
Sorrento Therapeutics, Inc.RetiradoSíndrome de distrés respiratorio agudo | SDRA